Jung Younsoo, Frisvold David, Dogan Timur, Dogan Meeshanthini, Philibert Rob
Cardio Diagnostics Inc., Coralville, IA 52241, USA.
Department of Economics, University of Iowa, Iowa City, IA 52242, USA.
Epigenomics. 2021 Apr;13(7):531-547. doi: 10.2217/epi-2021-0021. Epub 2021 Feb 24.
New epigenetically based methods for assessing risk for coronary heart disease may be more sensitive but are generally more costly than current methods. To understand their potential impact on healthcare spending, we conducted a cost-utility analysis. We compared costs using the new Epi + Gen CHD™ test with those of existing tests using a cohort Markov simulation model. We found that use of the new test was associated with both better survival and highly competitive negative incremental cost-effectiveness ratios ranging from -$42,000 to -$8000 per quality-adjusted life year for models with and without a secondary test. The new integrated genetic/epigenetic test will save money and lives under most real-world scenarios. Similar advantages may be seen for other epigenetic tests.
基于表观遗传学的新型冠心病风险评估方法可能更敏感，但通常比现有方法成本更高。为了解它们对医疗保健支出的潜在影响，我们进行了成本效益分析。我们使用队列马尔可夫模拟模型，将新型Epi + Gen CHD™检测的成本与现有检测的成本进行了比较。我们发现，使用新型检测与更好的生存率相关，并且对于有和没有二次检测的模型，其负面增量成本效益比极具竞争力，范围从每质量调整生命年-42,000美元到-8000美元。在大多数现实世界的情况下，新型综合基因/表观遗传学检测将节省资金并挽救生命。其他表观遗传学检测可能也有类似优势。
